Genomic Health, Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 4,500 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $57.09, for a total transaction of $256,905.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
James J. Vaughn also recently made the following trade(s):
- On Thursday, June 6th, James J. Vaughn sold 8,745 shares of Genomic Health stock. The shares were sold at an average price of $52.47, for a total transaction of $458,850.15.
Shares of GHDX stock opened at $56.20 on Friday. Genomic Health, Inc. has a 52-week low of $50.77 and a 52-week high of $92.18. The company has a market capitalization of $2.14 billion, a PE ratio of 53.52 and a beta of 1.07. The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.19. The firm has a 50 day simple moving average of $54.75.
Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, May 7th. The medical research company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.05. Genomic Health had a net margin of 10.35% and a return on equity of 18.70%. The firm had revenue of $108.80 million for the quarter, compared to analysts’ expectations of $106.75 million. During the same period last year, the firm earned ($0.11) earnings per share. The business’s revenue for the quarter was up 17.5% on a year-over-year basis. As a group, analysts forecast that Genomic Health, Inc. will post 1.46 EPS for the current year.
A number of equities analysts have issued reports on GHDX shares. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Beigene in a research note on Thursday, June 20th. Needham & Company LLC set a $69.00 price objective on shares of Genomic Health and gave the company a “buy” rating in a research note on Wednesday, June 19th. Canaccord Genuity raised their price objective on shares of ServiceNow from $285.00 to $300.00 and gave the company a “buy” rating in a research note on Wednesday, May 8th. Deutsche Bank set a $18.00 price objective on shares of Commercial Metals and gave the company a “buy” rating in a research note on Thursday, May 30th. Finally, BidaskClub raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 4th. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $64.86.
Several hedge funds and other institutional investors have recently made changes to their positions in GHDX. Norges Bank bought a new position in shares of Genomic Health during the fourth quarter worth $20,975,000. Fiera Capital Corp bought a new position in shares of Genomic Health during the first quarter worth $20,134,000. FMR LLC boosted its position in shares of Genomic Health by 83.8% during the fourth quarter. FMR LLC now owns 550,627 shares of the medical research company’s stock worth $35,466,000 after purchasing an additional 251,085 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of Genomic Health by 1,336.7% during the fourth quarter. Two Sigma Investments LP now owns 209,592 shares of the medical research company’s stock worth $13,500,000 after purchasing an additional 195,004 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Genomic Health by 269.2% during the first quarter. Assenagon Asset Management S.A. now owns 267,410 shares of the medical research company’s stock worth $18,732,000 after purchasing an additional 194,988 shares in the last quarter. 95.54% of the stock is currently owned by institutional investors.
About Genomic Health
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Featured Story: Outperform Rating
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.